FDA Approves Novel Schizophrenia Drug

The US Food and Drug Administration (FDA) recently approved a new treatment for schizophrenia that relies on a novel mechanism of action. Oral xanomeline and trospium chloride, marketed as Cobenfy, is the first antipsychotic drug authorized to treat the disease via cholinergic receptors instead of dopamine receptors, which has historically been the therapeutic pathway.